New horizons in treatment of multiple sclerosis

Abstract

For many years since 1866 a great number of authors has written about multiple sclerosis when Charcot mentioned it as the first. The most essential description was given by Appel in his publication Current Neurology. It was called The cruel medical mystery. Among all the methods of treatment, I would like to mention pharmacological one which has come from the observations made by Charcota and Babinski at the end of XIX century. A completely other look should be taken under consideration to the application of this theory. The main obstacle in the multiple sclerosis is eventually the disturbed transmission of nerve impulse and we should mostly focus on it. Although, we know more and more about patomechanism, unfortunately it still has minor influence on therapy in general use. The improvement of knowledge about immunological processes allows us to examine this disease more precisely. It helps us to introduce modifications in many areas. I must mention that in the past it was not always interpreted correctly. Moreover, the huge problem which prevents against the wide use of specific application is still the great cost of these clinical procedures. The influence of different medicines over clinical course of the disease is also under investigation in many medical centers. The most interesting thing seems to be the use of orally given pharmaceutical preparation instead of injections which are very uncomfortable for patients. Preparation which belong to the group of the most clinically examined The biggest researches are Fingolimodem (FTY720), Rituximabem, (Rituxan and Mabthera), Alemtuzumabem (Campath, MabCampath or Campath-1H) and vaccination against multiple sclerosis. New methods are directly taken from computerised neuroscience.